Actively Recruiting
TACTIC Coronary Thrombus Aspiration With Cath Rx In Anterior Myocardial Infarction: A Randomized Control Trial.
Led by Ceric Sàrl · Updated on 2026-04-21
140
Participants Needed
1
Research Sites
66 weeks
Total Duration
On this page
Sponsors
C
Ceric Sàrl
Lead Sponsor
E
European Cardiovascular Research Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this study is to evaluate the impact of sustained thrombectomy with INDIGO ASPIRATION SYSTEM using CAT RX versus no thrombectomy during primary percutaneous coronary intervention (PPCI) on microvascular obstruction and infarct size, as measured by cardiovascular magnetic resonance (CMR) between 3 and 5 days post PPCI, in patients with anterior STEMI
CONDITIONS
Official Title
TACTIC Coronary Thrombus Aspiration With Cath Rx In Anterior Myocardial Infarction: A Randomized Control Trial.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age >18 and <75 years old
- Acute anterior STEMI with ≥2 mm ST elevation in two or more contiguous anterior leads or ≥4 mm total ST-segment deviation sum in leads V1-V4 and anterior wall motion abnormality on ventriculogram or echocardiogram
- Culprit lesion in proximal or mid left anterior descending artery confirmed by coronary angiography
- TIMI thrombus grade >3 or TIMI flow 0 after guidewire crossing
- Presentation to hospital within 1 to 6 hours of ischemic pain onset
- Candidate for primary percutaneous coronary intervention (PPCI)
You will not qualify if you...
- Unable to give informed consent
- Life expectancy less than 1 year
- Contraindication to PCI
- STEMI due to stent thrombosis
- Spontaneous coronary artery dissection
- Prior maneuvers to restore flow before randomization
- Unwitnessed cardiac arrest or >30 minutes of CPR before enrollment or cardiac arrest with neurological impairment
- New stroke symptoms and NIHSS score >2 before procedure
- Known intolerance to aspirin, clopidogrel, ticagrelor, heparin, or contrast media
- Active severe bleeding
- Severe liver or kidney impairment
- Fibrinolytic therapy within 24 hours before enrollment
- Cardiogenic shock or need for mechanical circulatory support prior to catheterization
- Inferior STEMI or suspected right ventricular failure
- Severe valvular heart disease
- Acute cardiac mechanical complications such as ventricular wall rupture or acute mitral regurgitation
- Suspected or known pregnancy
- Suspected systemic active infection
- Known liver insufficiency before catheterization
- Undergoing renal replacement therapy
- COPD requiring home oxygen or chronic steroid therapy
- Contraindications to MRI or gadolinium use including creatinine clearance <30 mL/min, incompatible implants, or claustrophobia
- Prior myocardial infarction outside anterior territory
- Prior coronary bypass surgery or LAD PCI
- History of heart failure with ejection fraction <40% or recent hospitalization for heart failure
- Prior aortic valve surgery or transcatheter aortic valve replacement
- Left bundle branch block
- Stroke or transient ischemic attack within 3 months prior to screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Ospedale San Raffaele
Milan, Milani, Italy, 20132
Actively Recruiting
Research Team
P
Phani Krishna KONDAMUDI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here